demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID 19 outpatients
bamlanivimab monotherapy OPTIMISE-C19 ... BLAZE-1 phase 2 ... Rainwater-Lovett Bariola

0 studies excluded by filtering options 2